Clinical trial
Evaluating the Role of the Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy
NCT01517529 is registered in ClinicalTrials.gov with University of Cincinnati as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluating the Role of the Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy
- Lead sponsor
- University of Cincinnati
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 31, 2012
- Completion date
- December 31, 2014
- Enrollment
- 10 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.